tirzepatide 2025 Which Weight-Loss Drug Works the Best? 🧬 New data from the

Specific depletion of resident microglia in the early stage of stroke reduces cerebral ischemic damage

Patel K, Harrison SA, Elkhashab M et al (2020) Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial

Research shows it may help your body release more GLP-1, use insulin more effectively, and reduce inflammation

This fills in the nutritional gaps

The GIP receptor component provides complementary metabolic effects: Enhanced insulin sensitivity through direct action on adipose tissue Improved lipid metabolism via GIP-mediated effects on fat storage and mobilization Synergistic appetite suppression through combined incretin receptor activation in the hypothalamus Potentially better tolerated GI profile as GIP may partially offset GLP-1-mediated nausea Key Pharmacological Differences# Weight Loss Efficacy# Liraglutide (SCALE Program)# The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., NEJM 2015) was the pivotal trial for Saxenda approval: 3,731 adults without diabetes, liraglutide 3.0 mg daily for 56 weeks Mean weight loss: 8.0% (vs 2.6% placebo) 63.2% achieved 5% or more weight loss 33.1% achieved 10% or more weight loss Tirzepatide (SURMOUNT Program)# The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) established tirzepatide as a leading obesity treatment: 2,539 adults without diabetes, tirzepatide 5/10/15 mg weekly for 72 weeks Mean weight loss at 15 mg: 20.9% (vs 2.4% placebo) Mean weight loss at 10 mg: 21.4% Mean weight loss at 5 mg: 16.0% 63.2% achieved 20% or more weight loss at 15 mg Cross-Trial Comparison# While cross-trial comparisons have inherent limitations (different populations, durations, endpoints), the magnitude of difference is clear: Tirzepatide achieves approximately 2.8-fold greater mean weight loss, and the proportion reaching clinically meaningful thresholds is substantially higher across all categories